Recommendations for zoledronic acid treatment of patients with bone metastases.
about
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environmentToward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ RegimenReactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in ratsRare clinical experiences for surgical treatment of melanoma with osseous metastases in TaiwanZoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims databaseHMGB1 and cord blood: its role as immuno-adjuvant factor in innate immunity.Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy.Palliative radiation therapy in the management of brain metastases, spinal cord compression, and bone metastasesAssessment of the effects of zoledronic Acid therapy on bone metabolic indicators in hormone-resistant prostate cancer patients with bone metastatasis.Clinical management of pain in advanced lung cancer.Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases.Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation.Zoledronic acid in the management of metastatic bone disease.Osteonecrosis of the jaw and bisphosphonates: a comparison with white phosphorus, radium, and osteopetrosis.Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors.Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.The use of zoledronic acid in pediatric cancer patients.Pharmacokinetic evaluation of zoledronic acid.Zoledronic acid: multiplicity of use across the cancer continuum.Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy.Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study.A prospective randomized controlled clinical trial of zoledronic acid for bone metastases.Zoledronic acid in the management of metastatic bone diseaseAnalgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis.Osteonecrosis of the maxilla associated with the use of bisphosphonates.Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique.Intermolecular zero quantum coherences enable accurate temperature imaging in red bone marrow.Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
P2860
Q25255562-DF232D12-47A3-40A0-A42A-88CE41E3355FQ26749972-2D5974E2-212B-4241-805F-3E65BD586E90Q28540022-24227419-C7E2-48C8-8E59-847E2AAAEBC2Q30980121-7B3CB645-6C89-4F17-A22E-AD9897297B55Q33291614-B28112FA-F5D6-4B4D-B73F-978D8FD57BE6Q33978299-992FA84A-8073-4571-B933-49DFCF9397DDQ34018807-9385F3E2-EEE1-4514-ABA6-B440A964FD18Q34207923-8F8D59C8-EE12-4EB5-9D33-27E781463639Q34566891-47FE065C-4DDA-48E8-AF6B-1B44F4B125B8Q35377151-FB49A373-F20B-4B18-9D8E-B22D2F798716Q36327481-8FF172B6-6958-4286-8762-AC1F948F514AQ36505631-41DFB8FF-6185-4958-BF62-CD86FCFD6BFCQ36527045-489B2E40-98E3-4929-9C9F-199A630E79B5Q36568586-989615A4-7104-4336-9A3A-A1E2661698B6Q36708315-D8053646-721D-4DE2-9C12-337BFCF1BD65Q36939499-DA7DF945-AD80-4D18-AEA4-6E4BE33ADB3CQ36965659-FBCA4599-6481-493F-829D-F31B77730F0AQ37048841-C45CE20E-ADD8-4B8D-BAD5-E0730B43B90CQ37812612-4AF0C36D-1DA9-4B06-8FA1-BC4716702039Q37836669-96FB2ED9-3D2E-42D4-B3F4-901821B71FDCQ37874629-EA7359DC-AF95-4840-A3C9-02FC0BD7971CQ37909355-CF01FA88-9BBD-4AA2-BD0C-A1A8B726379CQ38153026-C5EDAC99-C08B-4EE0-8AF4-0D03107B3A5FQ38992409-C6921C4D-71B2-4FE3-8D25-84C241A57D3CQ39355581-C40FFA2C-B0E5-47BB-9102-7FCB2159605DQ41687221-1A33BAE8-582D-4E02-B1E8-D598F4F53EFEQ41864229-F7F22344-C69F-43A4-83F3-0C0290341764Q42792029-7EC68E75-3182-4B63-BF3F-BC7D213F1A44Q46396656-0F8273F1-29D2-4DE0-A299-C692C3A2C5C5Q50465080-624A1992-93B1-4BC1-9E9D-48CC37F31CFEQ53565333-6426F460-1DE9-4475-8FF7-8D2AFE953672
P2860
Recommendations for zoledronic acid treatment of patients with bone metastases.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Recommendations for zoledronic acid treatment of patients with bone metastases.
@ast
Recommendations for zoledronic acid treatment of patients with bone metastases.
@en
type
label
Recommendations for zoledronic acid treatment of patients with bone metastases.
@ast
Recommendations for zoledronic acid treatment of patients with bone metastases.
@en
prefLabel
Recommendations for zoledronic acid treatment of patients with bone metastases.
@ast
Recommendations for zoledronic acid treatment of patients with bone metastases.
@en
P1433
P1476
Recommendations for zoledronic acid treatment of patients with bone metastases.
@en
P2093
James R Berenson
P356
10.1634/THEONCOLOGIST.10-1-52
P577
2005-01-01T00:00:00Z